After publication of this article [1] , concerns were raised about the identity of one of the cell lines used in the study, the reporting of sequence information, and the representation of the western blot data.
A. Apoptosis in U251 and U87 cells was measured by Annexin V-FITC/propidium iodide (PI) staining following siZEB2 or control treatment. Early apoptotic cell populations were significantly increased (P<0.01) after siZEB2 transfection. B. Western blot analysis for antiapoptotic PARP and effector Caspase-3, Caspase-6 and Caspase-9. Decreased PARP and increased caspase-3,-6,-9, and Cleaved PARP expression were observed in U251 and U87 cells after ZEB2 downregulation at 72 hr post transfection. β-actin was used as a loading control. Representative β-actin loading controls are shown for PARP and cleaved PARP; corresponding β-actin loading control panels are not available for Caspase-3, correct image, and its associated β-actin panel is provided. Corresponding β-actin loading control panels are not available for Caspase-3, Caspase-6, and Caspase-9.
The available underlying western blots for Fig 7 are provided here as S2 File. The results of a repeat experiment carried out using a lentiviral shRNA vector to specifically and stably knock down the expression of ZEB2 in U87 cell lines are provided here as S3 File.
The PLOS ONE Editors issue this Expression of Concern to alert readers to the errors in the presentation of the western blots in Fig 7 and to the unavailability of both the individual-level data underlying the accompanying bar chart and the correct corresponding loading control images for the Caspase-3, Caspase-6, and Caspase-9 panels. 
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